This afternoon, TPG Pace Holdings Corp. (TPGH), filed an 8-K detailing the results of their shareholder vote, which was held earlier today, and shareholders overwhelmingly voted “yes’ to approve TPGH’s business combination with Accel Entertainment.
| FOR | AGAINST | ABSTAIN | BROKER NON-VOTES |
| 44,515,676 | 857,081 | 0 | 0 |
As you can see in the table above, only 857,081 shares voted “No”, which is just 1.9% of the shares that voted. The Company also announced today that it anticipates closing the transaction on Wednesday, November 20, 2019. We don’t have a formal press release as of yet, but we should get one shortly with anticipated new symbols. Furthermore, we’ll also most likely have to wait for additional information on number of redemptions and at what price, but for now, this is a nice result.
An update will be provided with additional details as they are released.
AGBA (NASDAQ:AGBA) stock is up over +90% this morning following a +211% premarket spike on news it has signed a definitive agreement to combine with social streaming video platform Triller. AGBA, the company itself, was formed by the $555 million combination between a SPAC of the same name and TAG Companies, a financial services firm...
At the SPAC of Dawn Since closing its combination with DHC last month, AI customer engagement firm BEN (NASDAQ:BNAI) has rolled out new partnerships with call center and healthcare clients. And, while it faces a fair bit of competition in the chatbot realm, several high-profile institutions have demonstrated that creating one that provides useful services...
Blue Ocean (NASDAQ:BOCN) provided significantly more texture today in the presentation for its $275 million combination with Asian digital media group TNL Mediagene, which it expects to hit profitability in the second half of the year despite a slight shakeup in financing for the transaction. The first big update in the first investor deck is...
At the SPAC of Dawn A brand new market may have just opened up for space de-SPACs as NASA administrator Bill Nelson announced a shift in the agency’s $11 billion program for a mission to return samples from Mars. Rather than rely on the agency’s internal technologies that would be predicted to get a sample...
Overall deal flow between SPACs and biotech firms has slowed over the last year, but some pending FDA changes could breathe new life into particular business models within the space. In particular, the FDA has asked Congress as part of its 2025 Legislative Proposals to eliminate the interchangeability designation for biosimilar medications, claiming the existing...